The European Hematology Association (EHA) 2026 conference, held from June 11th to 14th in Stockholm, Sweden, served as a pivotal…
Read More
ASCO 2026: Kelonia presents positive in vivo CAR-T data in multiple myeloma – Pharmaceutical Technology
The rapidly evolving landscape of multiple myeloma treatment is witnessing a pivotal moment with the emergence of in vivo chimeric…
Read More
Biogen Secures Global Rights to TJ Biopharma’s Felzartamab in Landmark $850 Million Deal, Aiming to Disrupt Multiple Myeloma Treatment Landscape
Biogen announced on April 20, 2026, a significant strategic acquisition, securing exclusive rights to TJ Biopharma’s novel anti-CD38 immunotherapy, felzartamab,…
Read More
Darzalex Secures Landmark European Approval for Self-Administration in Multiple Myeloma, Ushering in a New Era of Home-Based Cancer Care
Johnson & Johnson’s (J&J) groundbreaking cancer immunotherapy, Darzalex (daratumumab), has achieved a pivotal milestone in its European market penetration with…
Read More
